scholarly journals The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Kiyohide Fujimoto ◽  
Yoshihiko Hirao ◽  
Yasuo Ohashi ◽  
Yasuhiro Shibata ◽  
Kohzo Fuji ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostate Volume ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Chlormadinone Acetate ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Purpose. To evaluate the effects of chlormadinone acetate (CMA), progesterone-derived antiandrogen, on lower urinary tract symptoms (LUTS) and erectile functions of benign prostatic hyperplasia (BPH).Methods.A multicenter, single-cohort prospective study was conducted. A total of 114 patients received CMA for 16 weeks. The endpoints were changes in International Prostate Symptom Scores (IPSS), IPSS-QOL, International Index of Erectile Function-5,Qmaxprostate volume, and residual urine volume.Results.Significant improvements were observed in IPSS from week 8 to week 48 (32 weeks after treatment). IPSS-QOL improvements were also significant from week 8 to week 48.Qmaxincreased to a maximum at Week 16 and remained elevated throughout the study. Moreover, a decrease of 25% in prostate volume was observed at Week 16. IPSS, QOL, and Qmax changes during the study were not different between the previously treated and untreated patients. IPSS storage subscore changes differed between the age groups. Few severe adverse reactions were observed, except for erectile dysfunction.Conclusions.CMA rapidly and significantly reduced prostate volume and improved voiding and storage symptoms and QOL. Our results suggest that CMA is safe and beneficial, especially for elderly patients with LUTS associated with BPH.

COMPARING The EFFICACY AND SAFETY OF TREATMENT WITH FIXED DOSE OF TADALAFIL OR TAMSULOSIN AND THEIR COMBINATION THERAPY IN Patients With BENIGN PROSTATIC HYPERPLASIA and Erectile Dysfunction

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Hany Mostafa Abdallah ◽  
Ahmed Radwan ◽  
Kirolos Nabil Habib
Keyword(s):  
Erectile Dysfunction ◽  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Symptom Scores ◽  
Lower Urinary

Abstract Purpose To compare monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia and erectile dysfunction by comparing IPSS score, prostate volume and Qmax and some other outcomes. Materials and Methods All patients with lower urinary tract symptoms, benign prostatic hyperplasia and any grade of erectile dysfunction were recruited. They were randomly divided into three groups (50 participants in each group): Group A received 5 mg/daily tadalafil; Group B received 0.4 mg/daily tamsulosin; Group C receieved a combination of 0.4 mg/daily tamsulosin and 5 mg/daily tadalafil. Primary outcomes were prostate volume, prostate specific antigen, post-void residual volume, IPSS score, LUTS severity, Qmax, IIEF and erectile dysfunction severity and secondary outcome was complications. Results The mean ± SD of ultrasonographic prostate volume was 61.4 ± 15.1 mL and prostate specific antigen level was 2.4 ± 1.9 ng/dl. Post-void residual level was significantly different before and after the treatment, except for group A. Also, this group had no meaningful difference compared to the other groups in this regard (P > 0.05). There were significant differences between pre- and post-treatment international prostate symptom scores in each group (P < 0.05). Conclusion: Combination of tamsulosin and tadalafil can improve international prostate symptom scores, international index of erectile function questionnaire scores and Qmax in patients with lower urinary tract symptoms and benign prostatic hyperplasia to more degrees than their separate use. This combination is recommended because of its synergistic effects, well toleration and safety Conclusion Combination of tamsulosin and tadalafil can improve international prostate symptom scores, international index of erectile function questionnaire scores and Qmax in patients with lower urinary tract symptoms and benign prostatic hyperplasia to more degrees than their separate use. This combination is recommended because of its synergistic effects, well toleration and safety.

Sign in / Sign up

Export Citation Format

Share Document